Immix Biopharma Inc

NASDAQ IMMX

Data sourced from

and

Daily

Download Data

Immix Biopharma Inc Price to Sales Ratio (P/S) on June 03, 2024: 10,766.70

Immix Biopharma Inc Price to Sales Ratio (P/S) is 10,766.70 on June 03, 2024, a 3,383,142.08% change year over year. The price to sales ratio compares the market price per share of a company's stock to its sales revenue per share. It is calculated by dividing the market capitalization by the revenue, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's sales revenue. A higher ratio suggests that investors are willing to pay a higher price for each unit of sales revenue, indicating positive market sentiment and expectations for future revenue growth.

Immix Biopharma Inc 52-week high Price to Sales Ratio (P/S) is 13,913.89 on May 20, 2024, which is 29.23% above the current Price to Sales Ratio (P/S).
Immix Biopharma Inc 52-week low Price to Sales Ratio (P/S) is -1.51 on December 15, 2023, which is -100.01% below the current Price to Sales Ratio (P/S).
Immix Biopharma Inc average Price to Sales Ratio (P/S) for the last 52 weeks is 1,108.03.

NASDAQ: IMMX

Immix Biopharma Inc

CEO	Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
IPO Date	Dec. 16, 2021
Location	United States
Headquarters	11400 West Olympic Boulevard, Los Angeles, CA, United States, 90064
Employees	14
Sector	Healthcare
Industry	Biotechnology

Description

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Key trends